Skip to content Skip to footer

First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults   LITTLETON, Colo., April 9, 2024 — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS),…

Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET HIGHLANDS RANCH Colorado, March 31, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical…

Pioneer in Treating Dentofacial Abnormalities and / or Mild-to-Moderate Obstructive Sleep Apnea Ranks Among Top 10 Most Innovative Medical Device Companies of the Year HIGHLANDS RANCH Colorado, March 08, 2022…

The Vivos Method’s Proprietary Combination of Multidisciplinary Protocols and Oral Appliances Featured on New Corporate Website HIGHLANDS RANCH Colorado, March 03, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”)…

Vivos Therapeutics to Participate in Upcoming Investor Conferences HIGHLANDS RANCH Colorado, March 02, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on…

Vivos Medical Advisory Board to Expound on Clinical Data Set of Improved Patient Outcomes at One of the World’s Largest Sleep Conferences HIGHLANDS RANCH Colorado, February 24, 2022 HIGHLANDS RANCH,…

Vivos’ Continuous Clinical Improvement Program Yields Promising Data in AHI Score Reductions for Patients with Obstructive Sleep Apnea HIGHLANDS RANCH Colorado, January 27, 2022 Vivos Therapeutics, Inc. (“Vivos” or “the Company”)…

Vivos Also Announces Improved Pricing Agreement With SleepImage Dentists and Patients Report Exceptional User Experience with SleepImage Home Sleep Test HIGHLANDS RANCH Colorado, January 19, 2022 Vivos Therapeutics, Inc. (“Vivos” or…

mmRNA is the first and only appliance of its kind covered by Medicare Part of the Vivos System treatment, the mmRNA appliance represents a highly effective, nonsurgical, noninvasive, and nonpharmaceutical…

What’s Trending

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Tags